Lupin Limited (LUPIN) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹2,025 (+1.4% day change)
Key ratios
- P/E ratio
- 17.34
- P/B ratio
- 4.71
- ROE (%)
- 23.76
- ROCE (%)
- 26.82
- Debt/Equity
- 0.29
- Dividend yield (%)
- 0.52
- Market cap (₹ Cr)
- 92,601.22
Forensic checks
Piotroski F-Score: 7/9 · Altman Z-Score: 7.89 · Beneish M-Score: -2.68
InvestSights quality score
83.1/100 — High Quality (descriptive data-driven composite; not a recommendation)
Latest earnings call (Q2 FY27)
AI summary: The central signal is that Lupin’s near-term earnings profile is shifting from high-contribution U.S. exclusivity products toward a broader but more investment-intensive portfolio. Tolvaptan pricing pressure is expected to intensify, while Mirabegron faces additional competition after September next year; consequently, management views FY28 as a potential consolidation period…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.